COVID-19 treatment developed in St. Louis’ BioSTL Building to begin in-patient studies

Jun 17, 2020

A treatment for COVID-19 patients — developed in St. Louis by the team at Confluence Discovery Technologies as part of Aclaris Therapeutics — will begin human studies in a matter of days. The team is very excited about the potential for this drug and have been working with the FDA for the past three months to get approval to begin in-patient studies.

Confluence grew out of the BioGenerator Labs and was purchased by Aclaris Therapeutics in 2017. Confluence’s R&D has remained in St. Louis at The BioSTL Building.

Please see the news releases below on this milestone and background on Confluence’s exit.

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

BioGenerator-supported Confluence Life Sciences exit News Release